6 Results Found

Advanced Search

Select all

Results per page

Select all

Article

4 Citations

3,921 Views

15 Pages

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database

Giuseppe Cicala,
Michelangelo Rottura,
Viviana Maria Gianguzzo,
Federica Cristiano,
Selene Francesca Anna Drago,
Giovanni Pallio,
Natasha Irrera,
Egidio Imbalzano,
Edoardo Spina and
Vincenzo Arcoraci

Pharmaceuticals2024, 17(10), 1365;https://doi.org/10.3390/ph17101365

12 October 2024

Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments. The first PCSK9 antagonists (PCSK9-A), evolocumab and alirocumab, were approved in 2015...

Full Article

Review

29 Citations

7,836 Views

15 Pages

PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs

Nikolay Kuzmich,
Elena Andresyuk,
Yuri Porozov,
Vadim Tarasov,
Mikhail Samsonov,
Nina Preferanskaya,
Valery Veselov and
Renad Alyautdin

Molecules2022, 27(2), 434;https://doi.org/10.3390/molecules27020434

10 January 2022

PCSK9 has now become an important target to create new classes of lipid-lowering drugs. The prevention of its interaction with LDL receptors allows an increase in the number of these receptors on the surface of the cell membrane of hepatocytes, which...

Full Article

Review

28 Citations

5,019 Views

23 Pages

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach

Maria Francesca Greco,
Cesare R. Sirtori,
Alberto Corsini,
Marat Ezhov,
Tiziana Sampietro and
Massimiliano Ruscica

J. Clin. Med.2020, 9(7), 2103;https://doi.org/10.3390/jcm9072103

3 July 2020

It is well-known that elevated lipoprotein(a)—Lp(a)—levels are associated with a higher risk of cardiovascular (CV) mortality and all-cause mortality, although a standard pharmacotherapeutic approach is still undefined for patients with h...

Full Article

Review

3,082 Views

23 Pages

Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

Inderjeet Singh Bharaj,
Ajit Brar,
Aayushi Kacheria,
Karen Purewal,
Austin Simister,
Umabalan Thirupathy,
Palak Gupta,
Jasraj Kahlon,
Juzer Munaim and
Krishnaswami Vijayaraghavan
+ 3 authors

Biomedicines2025, 13(9), 2192;https://doi.org/10.3390/biomedicines13092192

8 September 2025

Cardiovascular-kidney-metabolic (CKM) syndrome is a multifaceted, systemic disorder characterized by the interplay of cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and obesity. This review synthesizes cu...

Full Article

Article

32 Citations

5,574 Views

17 Pages

TRPM2 Promotes Atherosclerotic Progression in a Mouse Model of Atherosclerosis

Yunting Zhang,
Fan Ying,
Xiaoyu Tian,
Zhenchuan Lei,
Xiao Li,
Chun-Yin Lo,
Jingxuan Li,
Liwen Jiang and
Xiaoqiang Yao

Cells2022, 11(9), 1423;https://doi.org/10.3390/cells11091423

22 April 2022

Atherosclerosis is a chronic inflammatory arterial disease characterized by build-up of atheromatous plaque, which narrows the lumen of arteries. Hypercholesterolemia and excessive oxidative stress in arterial walls are among the main causative facto...

Full Article

Article

6 Citations

1,726 Views

12 Pages

PAC1 Agonist Maxadilan Reduces Atherosclerotic Lesions in Hypercholesterolemic ApoE-Deficient Mice

Lilli Mey,
Gabriel A. Bonaterra,
Joy Hoffmann,
Hans Schwarzbach,
Anja Schwarz,
Lee E. Eiden,
Eberhard Weihe and
Ralf Kinscherf

Int. J. Mol. Sci.2024, 25(24), 13245;https://doi.org/10.3390/ijms252413245

10 December 2024

A possible involvement of immune- and vasoregulatory PACAP signaling at the PAC1 receptor in atherogenesis and plaque-associated vascular inflammation has been suggested. Therefore, we tested the PAC1 receptor agonist Maxadilan and the PAC1 selective...

Full Article